An *In vitro* Study on Anticancer Activity of Noscapine

Funda Karabağ Çoban¹, İbrahim Bulduk², İzzet İslam³ and Hande Aytuğ³

¹Department of Molecular Biology and Genetics, Faculty of Arts and Sciences, Usak University, Usak 64200, Turkey.
²Faculty of Health Sciences, Uşak University, Usak 64200, Turkey.
³Molecular Biology and Genetics A.D, Institute of Sciences, Usak University Usak 64200, Turkey.

Authors’ contributions

This work was carried out in collaboration among all authors. Author FKC designed the study, performed the statistical and biochemical analysis, wrote the protocol and wrote the first draft of the manuscript. Authors II, İB and HA managed the analyses of the study. Author İB managed the literature searches. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i1131246

Editors:

(1) Prof. John Yahya I. Elshimali, UCLA School of Medicine & Charles R. Drew University of Medicine and Science, USA.

Reviewers:

(1) Muhammad Irfan Bashir, Universiti Sains Malaysia, Malaysia.
(2) Shivanan L. Karigar, BLDE, Shri B. M. Patil Medical College, India.

Complete Peer review History: [http://www.sdiarticle4.com/review-history/66127](http://www.sdiarticle4.com/review-history/66127)

Received 28 December 2020
Accepted 02 March 2021
Published 15 March 2021

ABSTRACT

**Aims:** Breast cancer is the most common type of cancer among women and ranks second among the causes of female death in the world. In order to find a solution to breast cancer, different studies are being conducted for the treatment and the effects of different drugs and substances on this disease are intensively investigated. Boric acid has been shown to control the proliferation of certain types of cancer cells. Noscapine is one of the ingredients in Papaver somniferum (opium). It was first isolated from Papaver somniferum (opium) in 1817. It is one of the most abundant opioids found in the opium plant (up to 10% of the total composition) after morphine. It is also known as Narcotine, Nectodon, Nospen, Anarcotine, and (archaic) Opiane and occurs in the (±)-α isomer which has S, R stereochemistry (S stereochemistry at phthalide-carbon and R at isoquinoline-carbon). Noscapine is structurally and chemically different from other opium alkaloids such as morphine, codeine, thebaine, papaverine, and narceine.

**Materials and Methods:** Based on this information, this study was conducted in vitro to optimize the pure form of noscapine (obtained from the poppy capsule) by applying different concentrations...

*Corresponding author: E-mail: funda.karabagcoban@hotmail.com, funda.karabag@usak.edu.tr;*
with noscapine. PET scans were performed to evaluate the tumor volume and to estimate the overall tumor volume of each animal. The tumors were resected at the end of the experimental period (14 days) and subjected to histopathological examination to confirm the presence of adenocarcinoma. The results showed that the tumor volume and the overall tumor volume were significantly decreased in the noscapine group compared to the control group. The histopathological examination confirmed the presence of invasive ductal carcinoma in all the tumors.

Keywords: MCF-7, Noscapine, PARP, VEGF.

1. INTRODUCTION

Breast cancer is the most common disease that causes major health problems in women. It is in the first place among all cancer cases seen in women with a rate of 24.1% in our country. Although the incidence and prognosis vary according to geographical regions, it is reported that the incidence of breast cancer increases by 1.5% every year. It is reported in the literature that the most common type of breast cancer has the best survival because it has a 5-year survival rate of 75%. MCF-7 cells, a breast cancer cell line, were first isolated in 1970 from the pleural effusion of a 69-year-old woman of invasive ductal carcinoma. This cell line was established by Soule et al. The name MCF-7 is used as the abbreviation of Michigan Cancer Foundation -7. MCF-7, a commonly studied epithelial cancer cell line derived from breast adenocarcinoma, has the characteristics of differentiated breast epithelium. Today the treatments used for cancer are cytotoxic drugs that work somehow by interfering with functions of the cell's DNA. The identification of cytotoxic compounds has led to the development of anticancer therapy for years.

Noscapine closed molecular formula is C22H23NO7 with molar mass of 413.43 g / mol. Melting point of noscapine is about 176°C. The compound contains 63.91% C, 5.61% H, 3.39% N and 27.09% O atoms. Noscapine, which was previously thought to be narcotic, has been renamed when the antitussive (cough suppressant) property was discovered. It is the same as cough suppressant properties of codeine and because of its antitussive properties; it is used as a medication.

Noscapine, a cough suppressing agent, was discovered to be an antidrug in phase I / II trials for the treatment of bone marrow cancer. Noscapine does not change the tubulin monomer / polymer ratio. Thus, noscapine does not cause circular and neuronal toxicity. This is a feature on anti-microtubule drugs that both over polymerize currently available microtubules and break down polymers into monomers. Extensive studies have reported the potential benefit of noscapine in the treatment of lymphoma, melanoma, prostate, and lung cancer. Noscapine is an alkaloid with little or no effect on organs and blood parameters with low toxicity and also in cancer treatment. It has been reported that as the dose of noscapine increases, hydrogen peroxide production decreases with time. It has also been claimed that noscapine does not accumulate in various tissues. This may be due to the rapid destruction of noscapine in plasma and tissues. The pharmacokinetics studies of noscapine, showing that this drug is rapidly absorbed after oral administration and gives a maximum plasma concentration after 2-3 hours and can be undetectable after 6 hours, and circulates in the system in a short time.

2. MATERIALS AND METHODS

2.1 Sterilization Before Cell Culture

All plastic materials used in cell culture and ready-made sterile media were obtained from commercial companies. Following the incubation, the lysate and medium samples which prepared from the cells were analyzed using the methods described below.

2.2 Cell Culture

The main content of the medium used in the culture of MCF-7 human breast adenocarcinoma
cells is RPMI 1640, and it contains 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin. Cell culture was performed by incubating under sterile conditions in a carbon dioxide incubator providing 5% CO2 and 37°C temperature conditions. Sterile prepared medium for cell culture were prepared using T25 and T75 flasks. Passaging was performed when the cells that have been amplified reached a density of approximately 85% of the culture flask. Cells were used in experiments when they reached a sufficient number.

2.3 CCK 8 Cell Viability Test

For the CCK 8 cell viability test (ABP Biosciences AB1714A2), the cells were seeded in a 90-well plate at 90 tal in RPMI medium containing 10% FBS and 1% penicillin / streptomycin at 90 vel and incubated in a 5% CO 2 and 37 °C incubator. After 24 hours, the wells were divided into 8 groups as shown in Table 1. Three repetitions of each group were performed.

After applications, they were incubated for 48 hours. After 48 hours, 10 CCI of CCK 8 solution was added. Incubation was allowed for 2 hours. At the end of the incubation period, shaking for 10 seconds was applied and measurement at 450 nm wavelength with plate reader was performed.

2.4 PARP Analysis

Cells in 75 cm² flask were used for PARP analysis (Sun-Red 201911). Cells were removed with the aid of trypsin. After that, they were centrifuged and the supernatant was discarded and the resulting pellet was turned into suspension with the addition of medium.

24-well cell culture plates were used for the experiment. The MCF-7 human breast adenocarcinoma cell was seeded in wells at a density of 5x10⁵. The plates were allowed to stand in the incubator for 24 hours. Following incubation; the cells were treated with various concentrations of Boron. Then they were placed in a 37°C incubator for 48 hours. After 48 hours, the cells were removed from the incubator. Media from the plated cells were removed and treated with approximately 700μl of PBS. PBS was withdrawn from the treated cells. 200μl trypsin was added to the cells and placed in a 37°C incubator and cells were lifted. 450μl of medium was added to the cells separated from the surface to eliminate the effect of trypsin. The cells were transferred to the (eppendorf tube) for PARP by means of a disposable pipette. The cells in the eppendorf tube were centrifuged at 2100 rpm for 15 minutes at 15°C. After centrifugation, the supernatant was discarded. The medium was added to the eppendorf tube and gently mixed, then added to a 96-well plate loaded with single-use antibody in the kit. Reagents, samples and standards were prepared. Prepared samples and standards were seeded in a 96-well plate and allowed to incubate at 37°C for 60 minutes. After incubation, the
wells were washed with wash solution five times each. Chromogen solution A and B were added and incubation at 37°C for 10 minutes was allowed. The stop solution was then added and the measurement was performed.

2.6 Statistical Analysis

The data were analyzed using SPSS-18 computer program and the results were given as mean ± standard deviation (SD). After the homogeneity of the groups was tested, ANOVA-Duncan test were used in one-way to find differences between groups. Differences were considered statistically significant at P<0.05.

After applications, they were allowed to incubate for 48 hours. After 48 hours, 10 µL of CCK 8 solution was added. Incubation was allowed for 2 hours. At the end of the incubation period, they were shaken for 10 seconds and were measured at 450 nm wavelength with plate reader.

2.7 Determination of Noscapine Content from Poppy Capsule by HPLC

To determine the amount of Noscapine in this experiment;

Chromatographic analyzes were performed with Agilent brand 12660 HPLC device. UV-Vis detector was used. The device was controlled by ChemStation software.

Column: ACE brand (150 mm x 4.6 mm i. D. 5 µm) was used.

Mobile phase A: water containing 5% acetonitrile

Mobile phase B: Acetonitrile: Acetic acid: Triethylamine (97.9: 2: 0.1, v / v)

Flow rate: 1 ml / min;

Column temperature: 30°C;

Injection volume: 20 µl;

Detection: 284 nm;

Analysis time: 30 minutes.

Extract Preparation: 500 mg of dried ground poppy capsules were weighed and 30 ml of boiled deionized water was added to. The solution was stirred for 15 minutes. Then it was filtered and the pulp was thrown.

Gradient conditions:

Noscapine standard solutions: 1000 ppm Noscapine standard stock solution was prepared and then working standard solutions were prepared at concentrations (100, 200, 300, 400, 500 ppm) by diluting with water from the stock solution.

The poppy capsule was analyzed according to the specified analysis method. It was determined to contain 1.8% noscapine.

3. RESULTS

PARP and VEGF analyzes were performed on MCF-7 cell line treated with noscapine at 25 ppm, 50 ppm and 100 ppm concentrations. The results are given in Table 3.

| Groups  | Applications made                                      |
|---------|--------------------------------------------------------|
| Group 1 | RPMI with 10% FBS and 1% penicillin / streptomycin (Control) |
| Group 2 | 30 µM Cis Platin                                      |
| Group 3 | 5 ppm Noscapine Capsule                                |
| Group 4 | 10 ppm Noscapine Capsule                               |
| Group 5 | 25 ppm Noscapine Capsule                               |
| Group 6 | 50 ppm Noscapine Capsule                                |
| Group 7 | 75 ppm Noscapine Capsule                               |
| Group 8 | 100 ppm Noscapine Capsule                              |

Table 1. Groups created in the study

| Time (min) | Mobile phase A (%) | Mobile phase B (%) |
|------------|--------------------|--------------------|
| 0          | 90                 | 10                 |
| 5          | 85                 | 15                 |
| 10         | 80                 | 20                 |
| 20         | 65                 | 95                 |
| 30         | 90                 | 10                 |

Table 2. Gradient conditions
Table 3. PARP and VEGF results

|                | VEGF  | PARP    |
|----------------|-------|---------|
| Control        | 0.10±0.04<sup>a</sup> | 0.11±0.005<sup>a</sup> |
| Noscapine 25   | 0.09±0.02<sup>a</sup> | 0.05±0.002<sup>b</sup> |
| Noscapine 50   | 0.096±0.07<sup>a</sup> | 0.07±0.006<sup>ab</sup> |
| Noscapine 100  | 0.10±0.07<sup>a</sup> | 0.06±0.006<sup>b</sup> |
| Cis Platin     | 0.09±0.08<sup>a</sup> | 0.10±0.003<sup>a</sup> |

<sup>*a,b,c: Means in the same column by the same letter are not significantly different according to the one way ANOVA-Duncan test (P<0.05)</sup>

4. DISCUSSION

Noskapin is one of the ingredients in Papaver somniferum (opium). It was first isolated from Papaver somniferum (opium) in 1817. It is one of the most abundant opioids found in the opium plant (up to 10% of the total composition) after morphine.

It was used as an antitussive agent, but its antineoplastic property was later discovered in 1998. It works as a tubulin inhibitor by connecting stoichiometrically with the tubule, causing a change in its compliance. The development of plant-derived anticancer agents such as noscapine has been highlighted for the last 20 years.

Anticancer activity and synthesis of potent analogues of 9-12 noscapine, a plant-derived anticancer agent, have been reported. Structure-activity analysis has shown that the isoquinoline ring in noscapine (Nos) can be made without affecting the proton binding to tubulin at the C-9 position.[24,25] Due to its antitussive properties, noscapine is often used as an antitussive medication. [9, 11, 26] Based on this information, this study was conducted to investigate the effects of different concentrations of noscapine in MCF-7 breast cancer cell line.

MCF-7, MCF-10F, MDA-MD-231 cell lines were used in the study by Edwin and Gloria on the apoptotic effect of noscapine on breast cancer cell lines. MTT (3- (4,5-dimethylthiazol-2) -2,5-diphenyltetrazolium bromide) method was used to determine the cell viability of these cell lines. The IC-50 value for MCF-10F, MCF-7 and MDA-MB-231 cells at the end of 48 hours was determined as 53,30,20 µM, respectively, with varying doses of noscapine (20-100 µM). It has been shown to induce a concentration-
dependent cytotoxicity in MCF-10F, mcf-7 and MDA-MB-231 cells.[27]

In another study, Mahavir et al. investigated the anticancer activity of Noscapine, an opioid alkaloid, in combination with Cisplatin in human non-small cell lung cancer. Cell viability testing in each treatment group was determined by the crystal violet dye test. Cells were applied with various dilutions of Cis in the presence or absence of Nos at 10-30 and 30-50 µM, respectively, against H460 and A549 cells. Noscapine was found to inhibit proliferation of H460 and A549 cells in a dose-dependent manner with LD50 values of 34.7 ± 2.5 µM and 61.25 ± 5.6 µM, respectively.[28]

In another study; in human colon cancer cells, the SW480 cell line was used and the MTT method was performed to determine cell viability. Six groups (control, noscapine, negative control (NC), siCDH17, NC + noscapine and siCDH17 + noscapine) were used for testing cell viability. The study found that after treatment with 10 µg / mL noscapine, cell proliferation in siCDH17 + noscapine was significantly reduced compared to the noscapine group.[29] Arezou et al. studied the Synergistic Anticancer Effect of Paclitaxel and Noscapin on Human Prostate Cancer Cell Lines. In this study, the effect of noscapine (10-100) was tested using varying doses to LNCaP and PC-3 prostate cancer cell lines. At the end of 48th hour, the viability of cells was investigated by MTT method. As a result, they showed that single and combination therapies of both paclitaxel and noscapine significantly reduced the viability of both LNCaP and PC-3 cells compared to control cells in a dose and time dependent manner.[30]

In this study, cell viability test was performed using CCK-8 kit to examine the antiproliferative effects of noscapine and to determine the LD50 concentration.

Noscapine was applied to MCF-7 breast cancer cell line at concentrations of 5 ppm, 10 ppm, 25 ppm, 50 ppm, 75 ppm and 100 ppm. Directly a proportional reduction in cell proliferation was observed in the MCF-7 breast cancer cell line at 24, 48, and 72 hours, depending on concentration and time. However, as a result of the very high antiproliferative effect obtained in the 72 hour data, our study was conducted over the 48 hour incubation period, taking other studies as reference. LD50 value was determined as 50 ppm and other analyzes were made over this value.

Poly (ADP-Ribose) Polymerases (PARPs) belong to the family of enzymes that perform multiple cellular processes in addition to DNA repair. PARP1 is best characterized and is one of the PARPs activated by two DNA damage. Poly (ADPRibose) Polymerase (PARP, MA: 116 kDa) is one of the most abundant proteins in the nucleus. It catalyzes the polymerization of ADP-ribose from NAD + molecules in target cellular proteins by attaching to linear or branched polymers. PARP has many roles in most molecules and cellular processes such as DNA damage detection and repair, chromatin modifications, transcription and cellular death pathways. These processes are very critical in physiological and pathological outcomes such as genome repair, carcinogenesis, aging, inflammation, and neuron function.[31] PARP which is one of the first identified substrates of caspase has vital role especially in apoptosis and necrosis. In the apoptosis process, caspace 7 and caspase 3 cleave PARP between Asp214 and Gly215 and break down p85 and p25. The PARP cleavage separates DBD from the catalytic domain and inactivates the enzymes. This eliminates PARP activation in response to DNA fragmentation during apoptosis and hinders the necessary ATP consumption in necrotic cell death and the futile efforts required for DNA repair. Thus, PARP cleavage helps the cell enters the apoptotic pathway and is recognized as the distinctive feature of apoptosis.[31,32] PARP works according to the amount of damage in DNA. If DNA damage is very high, PARP leads the cell to necrosis with ATP / NAD consumption. If DNA damage is minimal, PARP, along with other DNA repair enzymes, can help the cell survive. Caspase, which plays a critical role in apoptosis and is the main responsible for the cleavage of PARP, when activated, the cell goes into apoptosis by performing PARP cleavage.[33] In this study, it was observed that PARP values decreased significantly compared to the control group and Cis Platin group. These results suggest that the applied noscapine concentrations lead to apoptotic death of cells. Although there is no significant difference between the Noscapine groups, the most effective concentration is 25 ppm.

Cancer cells secrete a number of angiogenic factors (VEGF, epidermal growth factor (EGF), and interleukin-18). Many of these factors act on different small vessels and their binding to the receptors in the endothelial cell, resulting in new vessels.[34, 35] The effects of Noscapine on VEGF were also examined, but no significant
difference was found between the control and Cis Platin groups and the noscapine groups.

5. CONCLUSION
As a result of the vitality test performed with the CCK-8 kit, it was determined that noscapine has an antiproliferative effect in various concentrations. PARP analysis has been done. As a result of the analysis, PARP levels were lower than the control group. This result suggests that the cells perform apoptotic death.

ETHICAL APPROVAL
As per international standard or university standard written ethical approval has been collected and preserved by the authors.

COMPETING INTERESTS
Authors have declared that no competing interests exist.

REFERENCES
1. T.C. Sağlık Bakanlığı Kanserle Savaş Politikası ve Kanser verileri, (1995–1999), Kanser Savaş Dairesi Başkanlığı Bakanlık Yayın No, 2002;168.
2. Yılmaz, MR. Meme kanserinin epidemiyolojisi ve etiyolojisi. Esin Emin Üstün (ed). Meme kanseri. Ayın Kitabı, Ege Üniversitesi Tıp Fakültesi Dekanlığı, Yayın Bürosu, İzmir, 2002;25-40.
3. Henson, HK. Meme kanseri ve Cinsellik. Sexuality and Disability, 2002;20(4):261-275. Çeviri: D. Aygın, Androloji Bülteni, sayı, 2004;19:366-7.
4. ThorsCL, Broeckel JA, Jacobsen PB. Sexual Functioning in Breast Cancer Survivors, Cancer Control, 2001; 8(5):442-448.
5. Soule, HD, Vazquez J, Long A, Albert S, & Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J NatlCancerInst, 1973; 51(5):1409-1416.
6. Chodosh, LA. Ekspression of BRCA1 and BRCA2 in normal and neoplastic cells. Journal of Mammary Gland Biology and Neoplasia, 1998; 3: 389-402Schwartzmann G, Winograd B, Pinedo HM. The main steps in the development of anticancer agents. Radiotherapy and oncology. 1988 Aug 1;12(4):301-13.
7. Önlmez, Hande. Papaver somniferum bitkisinden elde edilen alkaloidlerin ekstraksionunda kullanılan çözücü ve metodların karşılaştırılması. PhD diss., Selçuk Üniversitesi Fen Bilimleri Enstitüsü, 2007.
8. ATAKOL, Orhan and Yaşar Nabi KÜÇÜK. Türkiye’nin çeşitli yörelerinde yetiştirilen haşhaş bitkilerinden alkaloidlerin ekstraksiyonu ve ekstraktların susuz ortamlarda özelliklerinin incelenmesi. PhD diss., Ankara Üniversitesi Fen Bilimleri Enstitüsü Kimya Anabilim Dalı. 1996.
9. Merc Index, 1976
10. Tanker, Metin, and Nevin Tanker. Farmakognozi cilt 1. 2003.
11. Abdalla, Mohamed O., Prasanthi Karna, Hari Krishna Sajja, Hui Hao, Clayton Yates, Timothy Turner, and Ritu Aneja. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. Journal of controlled release 2011 Feb 10:149(3):314-22.
12. Landen, Jaren W., Vincent Hau, Mingshen Wang, Thomas Davis, Brian Ciliax, Bruce H. Wainer, Erwin G. Van Meir, Johnathan D. Glass, Harish C. Joshi, and David R. Archer. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clinical cancer research 2004 Aug 1;10(15):5187-201.
13. Ye, Keqiang, Yong Ke, Nagalakshmi Keshava, John Shanks, Judith A. Kapp, Rajeshwar R. Tekmal, John Petros, and Harish C. Joshi. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proceedings of the National Academy of Sciences 1998 Feb 17;95(4):1601-6.
14. Sioka, Chrissa, and Athanassios P. Kyritsis. Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer chemotherapy and pharmacology 2009 Apr 1;63(5):761-7.
15. Park, S. B., A. V. Krishnan, C. Lin, D. Goldstein, M. Friedlander, and M. C. Kiernan. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective
strategies. *Current medicinal chemistry* 2008 Dec 1;15(29):3081-94.
16. Ke, Yong, Keqiang Ye, Hans E. Grossniklaus, David R. Archer, Harish C. Joshi, and Judith A. Kapp. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. *Cancer Immunology, Immunotherapy* 2000 Jun 1;49(4-5):217-25.
17. Jackson, Tanise, Mahavir B. Chougule, Nkechi Ichite, Ram R. Pattolia, and Mandip Singh. Antitumor activity of noscapine in human non-small cell lung cancer xenograft model. *Cancer chemotherapy and pharmacology* 2008 Dec 1;63(1):117-26.
18. Singh, Harpal, Prashant Singh, Kamlesh Kumari, Ankush Chandra, Sujata K Dass, and Ramesh Chandra. A review on noscapine, and its impact on heme metabolism. *Current drug metabolism* 2013 Mar 1;14(3):351-60.
19. Bitoun, Emmanuelle, Alessia Micheloni, Laurence Lamant, Chrystelle Bonnart, Alessandro Tartaglia-Polcini, Christian Cobbold, Talal Al Saati et al. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome. *Human molecular genetics* 2003 Oct 1;12(19):2417-30.
20. Dahlström B, Mellstrand T, Löfdahl CG, Johansson M. Pharmacokinetic properties of noscapine. *European journal of clinical pharmacology*. 1982 Aug;22(6):535-9.
21. Karlsson MO, Dahlström B, Eckernäs SA, Johansson M, Alm AT. Pharmacokinetics of oral noscapine. *European journal of clinical pharmacology*. 1990 Sep;39(3):275-9.
22. Gökçe, Süleyman, Ibrahim Bulduk, and Hüseyin Enginar. Sıvı Kromatografisi Sıralı Kütle Spektroskopisi (LC-MS/MS) Tekniği İle Noskapin Ve İlgili Stres Bozunma Bileşiklerinin İncelenmesi Ve Tayini İçin Metot Optimizasyonu. *Düzce Üniversitesi Bilim ve Teknoloji Dergisi* 5.1: 231-241.
23. Rouleau, Michèle, Anand Patel, Michael J. Hendzel, Scott H. Kaufmann, and Guy G. Poirier. PARP inhibition: PARP1 and beyond. *Nature reviews cancer* 2010 Apr;10(4):293-301.
24. Zhu, Guangyu, Paul Chang, and Stephen J. Lippard. Recognition of platinum–DNA damage by poly (ADP-ribose) polymerase-1. *Biochemistry*. 2010 Jul 27;49(29):6177-83.
25. Önmez, Hande. Papaver somniferum bitkisinden edile edilen alkaloidlerin ekstraksiyonunda kullanılan çözücü ve metodların karşılaştırılması. PhD diss., Selçuk Üniversitesi Fen Bilimleri Enstitüsü, 2007.
26. Quisbert-Valenzuela, Edwin O., and Gloria M. Calaf. Apoptotic effect of noscapine in breast cancer cell lines. *International journal of oncology* 2016 Jun 1;48(6):2666-74.
27. Chougule, Mahavir, Apurva R. Patel, Pratik Sachdeva, Tanise Jackson, and Mandip Singh. Anticancer activity of Noscapine, an opioid alkaloid in combination with Cisplatin in human non-small cell lung cancer. *Lung cancer* 2011 Mar 1;71(3):271-82.
28. Tian, Xia, Meng Liu, Qingxi Zhu, Jie Tan, Weijie Liu, Yanfen Wang, Wei Chen et al. Down-regulation of liver-intestine cadherin enhances noscapine-induced apoptosis in human colon cancer cells. *Expert review of anticancer therapy* 2017 Sep 2;17(9):857-63.
29. Rabzia, Arezou, Mozafar Khazaei, Zahra Rashidi, and Mohammad Rasoul Khazaei. Synergistic anticancer effect of paclitaxel and noscapine on human prostate cancer cell lines. *Iranian journal of pharmaceutical research: IJPR* 2017;16(4):1432.
30. Elisa Cleaved PARP Kit, (2011), Katalog No: KHO0741, Invitrogen Corporation, Kalifornia, A.B.D. (www.invitrogen.com)
31. Chiarugi, Alberto, and Michael A. Moskowitz. PARP-1--a perpetrator of apoptotic cell death?(Perspectives: cell biology). *Science* 2002 Jul 12;297(5579):200-2.
32. Boulares, A. Hamid, Alexander G. Yakovlev, Vessela Ivanova, Bogdan A. Stoica, Geping Wang, Sudha Iyer, and Mark Smulon. Role of poly (ADP-ribose) polymerase (PARP) cleavage in apoptosis: caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. *Journal of Biological Chemistry* 1999 Aug 13;274(33):22932-40.
33. Hosmane, Narayan S., John A. Maguire, and Yinghuaie Zhu. *Boron and gadolinium neutron capture therapy for cancer treatment*. World Scientific, 2012.

34. Scorei, Romulus Ion, Cristina Ciofrangeanu, Raluca Ion, Anisoara Cimpean, Bianca Galateanu, Valentina Mitran, and Dana Iordachescu. In vitro effects of calcium fructoborate upon production of inflammatory mediators by LPS-stimulated RAW 264.7 macrophages. *Biological trace element research* 2010 Jun;135(1):334-44.

© 2021 Çoban et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/66127